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Abstract
Food intake and body weight are controlled by a variety of central and peripheral factors, but the exact mechanisms behind
these processes are still not fully understood. Here we show that that macrophage inhibitory cytokine-1 (MIC-1/GDF15),
known to have anorexigenic effects particularly in cancer, provides protection against the development of obesity. Both
under a normal chow diet and an obesogenic diet, the transgenic overexpression of MIC-1/GDF15 in mice leads to
decreased body weight and fat mass. This lean phenotype was associated with decreased spontaneous but not fasting-
induced food intake, on a background of unaltered energy expenditure and reduced physical activity. Importantly, the
overexpression of MIC-1/GDF15 improved glucose tolerance, both under normal and high fat-fed conditions. Altogether,
this work shows that the molecule MIC-1/GDF15 might be beneficial for the treatment of obesity as well as perturbations in
glucose homeostasis.
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Introduction
Macrophage inhibitory cytokine-1 (MIC-1/GDF15), also
known as GDF15, PLAB, NAG-1 or PTGFB, is a divergent
member of the TGF-beta family that was identified on the basis of
increased expression with macrophage activation [1]. In vivo and in
vitro experimentation suggests that MIC-1/GDF15 probably plays
an anti-inflammatory role, notably in mouse models of arthritis
and atherosclerosis [2]. In humans its circulating levels are
increased in chronic inflammatory diseases such as rheumatoid
arthritis and atherosclerosis [2]. Indeed, elevated MIC-1/GDF15
levels are an important risk factor for cardiovascular disease, as
well as a marker of poor outcomes and sub-optimal responses to
therapy [3]. MIC-1/GDF15 is also expressed by many common
cancers, and its serum levels rise approximately in proportion to
the stage and extent of disease, providing a potential clinical tool to
aid in prevention, diagnosis and prognosis [4]. Serum levels of
MIC-1/GDF15 are an independent predictor of all cause
mortality [5]. Substantial elevation of circulating MIC-1/GDF15
levels in cancers and other diseases such as chronic renal or
cardiac failure are associated with a lower body mass index and
sometimes cachexia [2,6], suggesting that apart from any role in
inflammation in disease, MIC-1/GDF15 may also play a role in
body weight regulation.
Xenograft of MIC-1/GDF15 expressing human prostate cancer
cells into mice leads to loss of fat and lean body mass, and this
appears to be directly due to decreased food intake [6].
Administration of anti-MIC-1/GDF15 neutralizing antibodies
completely reversed the effects of xenograft-derived MIC-1/
GDF15, confirming that the effects were directly mediated by
MIC-1/GDF15 production. Weight loss and anorexia could also
be induced acutely in mice by administration of recombinant
MIC-1/GDF15, an effect mediated via the direct action of MIC-
1/GDF15 in areas of the brain that regulate appetite [6].
Interestingly, people with anorexia nervosa or obesity also exhibit
elevated circulating MIC-1/GDF15 levels, and obese people with
type 2 diabetes exhibit still further elevations in MIC-1/GDF15
compared to non-diabetic obese patients [7]. These findings
suggest that in addition to the central regulation of food intake,
MIC-1/GDF15 may play a role in regulating metabolism and
glucose homeostasis.
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duced by organs and tissues involved in the control of metabolism,
notably the liver and white adipose tissue [8]. This further suggests
that MIC-1/GDF15 could be a metabolic regulator. In white
adipose tissue, both macrophages of the stromal vascular fraction
and adipocytes release MIC-1/GDF15, indicating that it also acts
as an adipokine. Adipokines such as adiponectin and leptin, both
of which regulate MIC-1/GDF15 release from adipocytes [8], are
involved in the regulation of body weight and insulin sensitivity
[9]. An additional regulator of both MIC-1/GDF15 release and
energy homeostasis is insulin. Circulating MIC-1/GDF15 levels
were significantly increased after a two-hour euglycemic hyperin-
sulinemic clamp in normal control and obese subjects, as well as in
those with anorexia nervosa [10]. An inverse correlation between
circulating MIC-1/GDF15 levels and insulin sensitivity was also
observed, with less insulin sensitive subjects having higher
circulating MIC-1/GDF15 levels, further suggesting that MIC-
1/GDF15 may regulate peripheral metabolism.
While the above-mentioned reports show increased circulating
levels of MIC-1/GDF15 under conditions of altered adiposity and
insulin responsiveness, whether MIC-1/GDF15 is a cause or a
consequence of these metabolic alterations remains unknown. To
help clarify this issue we determined the effects of chronically
increased MIC-1/GDF15 levels on food intake, body weight, body
composition, energy metabolism and glucose homeostasis, both
under conditions of a normal chow and an obesogenic (high fat)
diet, using mice overexpressing MIC-1/GDF15 under the control
of the macrophage-specific colony-stimulating factor-1 receptor
promoter (MIC-1
fms) versus wild type control mice (MIC-1
+/+).
Results
MIC-1/GDF15 overexpression is associated with a lean
phenotype and hypophagia
In mice on the normal chow diet, overexpression of MIC-1/
GDF15 lead to a significant reduction in body weight from 11 to
24 weeks of age (Fig. 1A). This reduction in body weight in the
MIC-1
fms transgenic mice was correlated with decreases in
absolute (Fig. 1B) and relative (Fig. 1C) whole body fat mass as
determined by dual energy X-ray absorptiometry (DXA) at 26
weeks of age. The absolute lean mass of MIC-1/GDF15
transgenic mice was also significantly reduced relative to that of
wild type controls (Fig. 1D), but not when normalized to their
reduced body weight (Fig. 1E), demonstrating a disproportionate
decrease in fat but not lean mass in the transgenic animals. The
reduced fat mass of transgenic mice, as determined by DXA, was
associated with significant decreases in the mass of dissected white
adipose tissue (WAT) depots, both when expressed as absolute
weight (Fig. 1F), or when normalized to body weight (Fig. 1G).
The absolute (Fig. 1H) and normalized (Fig. 1I) mass of brown
adipose tissue (BAT) of MIC-1/GDF15 transgenic mice was not
significantly reduced compared to that of control mice.
In order to investigate the reasons for their leaner phenotype,
we first looked at food intake in MIC-1
fms mice. Indeed, 24-hour
spontaneous food intake, either normalized to body weight
(Fig. 1J), or expressed as an absolute value (data not shown), was
significantly reduced. However, the anorexigenic effect of MIC-1/
GDF15 was not seen during re-feeding after a 24-hour fast, either
when food intake was expressed as absolute weight (Fig. 1K) or as
a percent of body weight (data not shown), suggesting that MIC-1/
GDF15 has anorexigenic effects mainly under non-fasted
conditions. Interestingly, compared to wild type controls, mice
overexpressing MIC-1/GDF15 lost significantly more weight and
exhibited significantly delayed weight regain after 24-hour fasting
(Fig. 1L). The lean phenotype of the normal chow-fed MIC-1/
GDF15 transgenic mice did not appear to result from alteration of
their metabolic phenotype, as the respiratory exchange ratio
(RER) of transgenic animals was similar to that of control mice
(Fig. 1M), indicating similar use of lipids and carbohydrates as
energetic fuel sources. Energy expenditure normalized to lean
mass was also similar between MIC-1/GDF15 transgenic and
control mice (Fig. 1N). Finally, MIC-1/GDF15 transgenic mice
exhibited significantly decreased physical activity relative to that of
control mice at the start of the dark phase (Fig. 1O), indicating that
the lean phenotype of the transgenic mice was not due to
hyperactive behaviour. Overall, these results show that transgenic
overexpression of MIC-1/GDF15 in normal chow-fed mice is
associated with a lean phenotype due to decreased food intake but
not to alteration of energy metabolism.
Overexpression of MIC-1/GDF15 improves glucose
tolerance
Differences in body weight and composition are frequently
associated with alterations in glucose tolerance. We thus measured
the ability of normal chow-fed MIC-1/GDF15 transgenic mice to
clear glucose from the circulation using an intraperitoneal glucose
tolerance test. We found a significant improvement in glucose
tolerance in the transgenic mice at early time points after glucose
injection (Fig. 2A), with the resultant area under the glucose curve
being significantly lower in transgenic versus control mice (Fig. 2B).
MIC-1/GDF15 transgenic mice also demonstrated significantly
reduced blood glucose levels in response to an intraperitoneal
insulin tolerance test (Fig. 2C), suggesting that the improved
glucose tolerance of these mice may be due to improved insulin
responsiveness. We did not observe any significant difference in
non-fasted serum insulin levels in normal chow-fed MIC-1
fms
transgenic versus MIC-1
+/+ control mice (51.5610.3 pM in MIC-
1
fms versus 69.1619.1 pM in controls, n=5 mice per group).
Weight gain, glucose intolerance and reduced insulin responsive-
ness are hallmarks of obesity. We thus aimed to determine whether
MIC-1/GDF15 transgenic overexpression would have beneficial
effects on body weight and glucose homeostasis under obesogenic
conditions.
MIC-1/GDF15 reduces body weight and adiposity under
obesogenic conditions
Our high fat diet induced significant increases in body weight
and adiposity in both MIC-1
+/+ control mice and MIC-1
fms
transgenic animals. For instance, body weight and % adiposity (as
determined by DXA) at 24–26 weeks of age in chow-fed
MIC-1
+/+, high fat-fed MIC-1
+/+, chow-fed MIC-1
fms and high
fat-fed MIC-1
fms animals was 22.160.14, 25.5560.98, 20.4860.44
and 22.4460.61 g and 14.4660.65, 29.1261.46, 12.7660.24 and
26.161.29%, respectively (data are means6SEM of 5 female mice
per group. p,0.01 for the effects of genotype, diet and the
interaction). It is noteworthy that MIC-1/GDF15 transgenic mice
fed a high fat diet retain a significantly lower body weight relative to
wildtype counterparts, particularly from the tenth week on the diet
onwards (Fig. 3A). Contrary to what was observed in the normal
chow fed group, the absolute and relative total body fat mass
(Fig. 3B–C) and lean mass (Fig. 3D–E) of high fat-fed MIC-1/
GDF15 transgenic mice – as determined by DXA – were not
significantly reduced relative to that of control mice. However, the
absolute (Fig. 3F) and relative (Fig. 3G) weights of individual
dissected WAT depots were significantly reduced in transgenic
versus wild type mice at the end of the experiment. In contrast to
the WAT, BAT mass was similar between MIC-1/GDF15
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under conditions of a normal chow diet, MIC-1/GDF15 transgenic
mice fed a high fat diet exhibited significantly reduced food intake,
either when normalized with body weight (Fig. 3J) or as absolute
values (data not shown). Thus, the anorexigenic effect of transgenic
MIC-1/GDF15 overexpressionisnotdependenton the caloriclevel
of the diet. However, this anorexigenic effect depends on the
prevailing nutritional status, because after a 24-hour fast, the MIC-
1/GDF15transgenicmicehad a similar intakeof the highfatdiet to
that of controls (Fig. 3K), similar to data observed in normal chow-
fed animals (Fig. 1K). Contrary to what was observed in normal
chow-fed animals, weight loss after fasting was similar between mice
overexpressing MIC-1/GDF15 and control mice on the high fat
diet (Fig. 3L).
Metabolism of the high fat-fed MIC-1/GDF15 transgenic mice
was impaired, as indicated by their RER being significantly
different from that of control mice (Fig. 3M). However, energy
expenditure normalized to lean mass was similar between
genotypes (Fig. 3N). Finally, similar to observations in normal
chow-fed animals, the MIC-1/GDF15 transgenic mice on a high
fat diet exhibited significantly decreased ambulatory activity,
notable during the first part of the dark phase (Fig. 3O).
Altogether, these data suggest that MIC-1/GDF15 overexpression
leads to a leaner phenotype under obesogenic conditions, probably
due to decreased food intake.
MIC-1/GDF15 overexpression improves glucose tolerance
in mice on a high fat diet
As we observed under normal chow fed conditions, in high fat-
fed mice the overexpression of MIC-1/GDF15 significantly
improved glucose tolerance in response to intraperitoneal glucose
injection (Fig. 4A). The area under the curve of the glucose
tolerance test was decreased in the high fat-fed MIC-1/GDF15
transgenic mice compared to corresponding control mice, but this
fell just short of statistical significance (Fig. 4B). Unlike in chow-fed
animals, this improvement in glucose tolerance was not likely due
to increased insulin responsiveness, as the change in blood glucose
during an insulin tolerance test was not significantly different
between genotypes (Fig. 4C). As in the normal chow-fed animals,
we did not observe any significant difference in non-fasted serum
insulin levels in MIC-1
fms transgenic versus MIC-1
+/+ control
mice on the high fat diet (62.769.0 pM in MIC-1
fms versus
115.3624.6 pM in controls, n=5 mice per group, p=0.07).
Altogether these data show that the overexpression of MIC-1/
GDF15 improves glucose tolerance, both under chow-fed
conditions as well as under obesogenic conditions.
Discussion
In the present study we demonstrate that long-term elevated
expression of MIC-1/GDF15 in mice leads to decreases in food
intake, body weight and adiposity with concomitantly improved
glucose tolerance, both under normal and obesogenic dietary
conditions. As these mice do not exhibit any increases in energy
expenditure or ambulatory activity, the lean phenotype of mice
Figure 1. MIC-1/GDF15 overexpression reduces body weight, adiposity and food intake without altering metabolism. A. Body weight
of mice overexpressing MIC-1/GDF15 (MIC-1
fms) and control mice (MIC-1
+/+) from 11 to 24 weeks of age, represented as 0–13 weeks on the normal
chow diet. B–E. Absolute and relative (as a percent of body weight) fat and lean mass as determined by dual energy X-ray absorptiometry (DXA) in
normal chow-fed MIC-1
fms and MIC-1
+/+ control mice at 26 weeks of age. F–I Mass of white adipose tissue (WAT) and interscaptular brown adipose
tissue depots as absolute weight (F, H) or normalized to body weight (G, I) in normal chow-fed MIC-1
fms and MIC-1
+/+ control mice at 26 weeks of age.
i, inguinal; p, periovarian; r, retroperitoneal and m, mesenteric WAT depots. J–K. Spontaneous (J) and cumulative 24-hour fasting-induced food intake
(K), normalized to body weight, measured over 24 hours in normal chow-fed MIC-1
fms and MIC-1
+/+ control mice at 25 weeks of age. L. Body weight
of 25 week-old normal chow-fed MIC-1
fms and MIC-1
+/+ control mice before 24 hour fasting and at the indicated time points after re-introduction of
food, with 100% representing pre-fasting body weight. M–O. Respiratory exchange ratio (RER, M), energy expenditure normalized to lean mass as
determined by DXA (N) and ambulatory activity (O) of normal chow-fed MIC-1
fms and MIC-1
+/+ control mice at 26 weeks of age. Data are means 6
SEM of 5 female mice per group. *p,0.05, **p,0.01 and ***p,0.001 for the difference between genotypes.
doi:10.1371/journal.pone.0034868.g001
Figure 2. MIC-1/GDF15 overexpression improves glucose tolerance and response to insulin. A. Blood glucose concentrations in response
to i.p. glucose injection (1 g/kg) in normal chow-fed mice overexpressing MIC-1/GDF15 (MIC-1
fms) and control mice (MIC-1
+/+) at 23 weeks of age. B.
Area under the curve calculated from the glucose tolerance test in (A). C. Blood glucose concentrations in response to i.p. insulin injection (1 U/kg) in
normal chow-fed MIC-1
fms and MIC-1
+/+ mice at 24 weeks of age. Data are means 6 SEM of 5 female mice per group. *p,0.05, **p,0.01 and
***p,0.001 for the difference between genotypes.
doi:10.1371/journal.pone.0034868.g002
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PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e34868Figure 3. MIC-1/GDF15 overexpression reduces body weight, adiposity and food intake in high fat-fed mice. A. Body weight of mice
overexpressing MIC-1/GDF15 (MIC-1
fms) and control mice (MIC-1
+/+) from 11 to 24 weeks of age, at 0–13 weeks on a high fat diet. B–E. Absolute and
relative (as a percent of body weight) fat and lean mass as determined by dual energy X-ray absorptiometry (DXA) in MIC-1
fms and MIC-1
+/+ control
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ic effect of MIC-1. These results suggest a promising therapeutic
potential for MIC-1/GDF15 in the treatment of obesity and
perhaps in pre-diabetic glucose intolerance.
Unlike other members of the TGF-beta superfamily, which
have been shown to modulate body weight and composition by
directly influencing adipose tissue development and function, our
data suggest that MIC-1/GDF15 mediates its effects by decreasing
food intake. For instance, mice that are deficient in SMAD4, the
canonical TGF-beta signalling pathway molecule that is used by
most TGF superfamily members, do not exhibit hypophagia.
Instead, their reduced body weight is likely due to alterations in
white and brown adipose tissue metabolism [11]. We could find no
evidence that MIC-1/GDF15 has peripheral effects on adipose
tissue metabolism. The respiratory exchange ratio of MIC-1/
GDF15 transgenic animals was not decreased, as would have been
expected if their lean phenotype were mediated by greater fat
oxidation [12]. Bone morphogenic protein-7 (BMP-7), another
member of the TGF-beta superfamily, has been shown to mediate
weight loss by promoting brown adipose tissue (BAT) develop-
ment. Indeed, mice with increased BMP-7 expression had higher
BAT mass contributing to the associated increase in energy
expenditure [13]. We observed no such effect in MIC-1/GDF15
transgenic mice, which exhibited either relatively decreased or
unchanged brown adipose tissue mass and similar energy
expenditure compared to syngenic controls, both under the
normal or obesogenic diets. Taken together, these results suggest
that overexpression of MIC-1/GDF15 may not contribute to
leanness due to peripheral effects of MIC-1/GDF15 on white or
brown adipose tissue development or functionality.
This work shows that like other TGF-beta family members,
MIC-1/GDF15 might be a promising target to reduce body
weight under obese conditions with a major anorexigenic effect. It
is interesting to note that contrary to the anorexigenic cytokine
leptin, to which peripheral resistance develops from 8 weeks on a
high fat diet [14], there is no obvious resistance to the anorexigenic
effects of MIC-1/GDF15 even after 14 weeks on the high fat diet,
when MIC-1/GDF15 transgenic mice still eat less than congenic
controls. We have previously shown that the anorexigenic effects
of MIC-1/GDF15 are mediated through a direct effect on
hypothalamic arcuate nucleus neurons by a 47% increase in the
expression of pro-opiomelanocortin (POMC), the precursor to the
anorexigenic alpha melanocyte stimulating hormone (a-MSH),
and a 34% decrease in that of the orexigenic neuropeptide Y
(NPY), and that this process involves binding to TGF-beta
receptor II [6]. The current work extends these findings by
showing that this effect of MIC-1/GDF15 on POMC and NPY
expression might be overwhelmed in fasted conditions, where
hypothalamic arcuate nucleus POMC expression is reduced and
that of NPY is upregulated [15], because the MIC-1/GDF15
transgenic mice do not exhibit reduced food intake after fasting.
Moreover, if MIC-1/GDF15 has a stronger effect on POMC than
on NPY neurons, as indicated by the changes in POMC and NPY
expression in the arcuate nucleus as described above [6], then
increased POMC expression may be a major contributor to the
phenotype of MIC-1
fms mice, as POMC knockout animals exhibit
an obese phenotype [16] whereas NPY knockouts remains lean
under basal conditions on a normal chow fed [17]. Thus, long-
term MIC-1/GDF15 overexpression has sustained anorexigenic
effects under both normal and obesogenic conditions, but these
effects are not observed in conditions of re-feeding after fasting.
Beneficial roles of MIC-1/GDF15 overexpression are not
restricted to reduced body weight and adiposity, as we also show
improved glucose tolerance in MIC-1/GDF15 transgenic mice.
mice at 26 weeks of age, after 15 weeks on the high fat diet. F–I Mass of white adipose tissue (WAT) and interscapular brown adipose tissue depots as
absolute weight (F, H) or normalized to body weight (G, I) in high fat-fed MIC-1
fms and MIC-1
+/+ control mice at 26 weeks of age. i, inguinal; p,
periovarian; r, retroperitoneal and m, mesenteric WAT depots. J–K. Spontaneous (J) and cumulative 24-hour fasting-induced food intake (K),
normalized to body weight, measured over 24 hours in high fat-fed MIC-1
fms and MIC-1
+/+ control mice at 25 weeks of age. L. Body weight of 25
week-old high fat-fed MIC-1
fms and MIC-1
+/+ control mice before 24 hour fasting and at the indicated time points after re-introduction of food, with
100% representing pre-fasting body weight. M–O. Respiratory exchange ratio (RER, M), energy expenditure normalized to lean mass as determined by
DXA (N) and ambulatory activity (O) of high fat-fed MIC-1
fms and MIC-1
+/+ control mice at 26 weeks of age. Data are means 6 SEM of 5 female mice
per group. *p,0.05, **p,0.01 and ***p,0.001 for the difference between genotypes.
doi:10.1371/journal.pone.0034868.g003
Figure 4. MIC-1/GDF15 overexpression improves glucose tolerance in mice on a high fat diet. A. Blood glucose concentrations in
response to i.p. glucose injection (1 g/kg) in mice overexpressing MIC-1/GDF15 (MIC-1
fms) and control mice (MIC-1
+/+) at 23 weeks of age, after 13
weeks on a high fat diet. B. Area under the curve calculated from the glucose tolerance test in (A). C. Blood glucose concentrations in response to i.p.
insulin injection (1 U/kg) in MIC-1
fms and MIC-1
+/+ mice at 24 weeks of age, after 14 weeks on a high fat diet. Data are means 6 SEM of 5 female mice
per group. *p,0.05, **p,0.01 and ***p,0.001 for the difference between genotypes.
doi:10.1371/journal.pone.0034868.g004
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improved insulin action rather than increased insulin secretion,
because the hypoglycaemic response to insulin was enhanced in
MIC-1/GDF15 transgenic animals, at least under normal chow-
fed conditions, and because transgenic mice showed no evidence
of increased circulating insulin levels. Lean mass and fat mass have
been shown to modulate glucose homeostasis, with greater lean
mass or reduced fat mass being associated with improved glucose
tolerance. Both under normal and obesogenic conditions, MIC-1/
GDF15 overexpressing mice have a similar percentage lean mass
compared to control mice, demonstrating that MIC-1/GDF15
does not improve glucose tolerance by modulating lean mass. In
contrast, the possible contribution of reduced adiposity to the
improved glucose tolerance of MIC-1/GDF15 transgenic mice
cannot be excluded. Additionally, the effect of MIC-1/GDF15 on
glucose homeostasis could be mediated via central mechanisms as
described for insulin [18], as is the case for its effects on food
intake. Further work would be required to test this hypothesis. It is
of interest that the effects of MIC-1/GDF15 over expression on
glucose and insulin tolerance were more pronounced in animals
on the chow diet than on the high fat diet. The effects of MIC-1/
GDF15 to increase hypothalamic POMC expression and decrease
that of NPY [6] could conceivably contribute to the improved
glucose tolerance or heightened response to insulin in MIC-1
fms
mice. Indeed, administration of agents that mimic the action of
alpha melanocyte stimulating hormone (a-MSH), the anorex-
igeneic product of the POMC gene, improves the response to
insulin in rats [19], whereas central administration of NPY to rats
induces muscle insulin resistance [20]. However, because chronic
consumption of a high fat diet significantly influences hypotha-
lamic POMC and NPY expression in rodents [21,22], such
changes could contribute to attenuation of the effects of MIC-1/
GDF15 over expression on glucose homeostasis under high fat
feeding conditions. Taken together, we show that MIC-1/GDF15
improves glucose tolerance by a mechanism likely to involve
improved insulin action rather than increased secretion, and that
this effect may be mediated by reduced adiposity as well as by a
possible role of the central nervous system.
Altogether, this study shows that long-term overexpression of
MIC-1/GDF15 reduces body weight and adiposity and improves
glucose homeostasis under normal and obesogenic conditions.
Thus, MIC-1/GDF15 might provide the basis for a promising
therapeutic to improve obesity and its associated metabolic
complications.
Materials and Methods
Ethics statement and animals
All research and animal care procedures were approved by the
Garvan Institute/St Vincent’s Hospital Animal Experimentation
Ethics Committee (Ethics No: HH #08/01) and were in
agreement with the Australian Code of Practice for the Care
and Use of Animals for Scientific Purpose. Methods for generation
of the MIC-1/GDF15 overexpressing mice on a C57BL6J
background were published previously [6]. Overexpression of
MIC-1 was under the control of the macrophage-specific colony-
stimulating factor-1 receptor promoter (fms), and hence transgenic
mice are referred to as MIC-1
fms. C57BL/6J mice (ARC, Canning
Vale, WA, Australia) were used as controls, and these are referred
to as MIC-1
+/+. We have previously shown that compared to
MIC-1
+/+ control mice, MIC-1
fms have an over 35-fold increase in
MIC-1 mRNA levels in the spleen, and an approximately 90-fold
increase in relative serum MIC-1 levels, a fold increase that has
been observed in patients with cancer [6]. Mice were housed
under conditions of controlled temperature (22uC) and illumina-
tion (12-h light cycle, lights on at 0700 h). Unless otherwise stated,
mice had ad libitum access to food and water. The diet was either
normal chow (6% calories from fat, 21% calories from protein,
71% calories from carbohydrates, 2.6 kcal/kg; Gordon’s Specialty
Stock Feeds, Yanderra, NSW, Australia) or a high fat diet (43%
calories from fat, 17% calories from protein, 40% calories from
carbohydrate, 4.7% calories from crude fibre, 4.7% calories from
acid detergent fibre, 4.78 kcal/kg; Specialty Feeds, Glen Forrest,
WA, Australia). The high fat diet was commenced at 10 weeks of
age. All experiments were performed on female mice.
Assessment of body weight and composition
Mice were weighed once a week from the age of 11 weeks to 24
weeks. Upon completion of indirect calorimetry and physical
activity measurements as described below, animals were anesthe-
tized with isoflurane and scanned using dual-energy X-ray
absorptiometry (DXA) (Lunar PIXImus; GE Healthcare, WI,
USA) to determine whole body fat and lean mass. The head was
excluded from analyses of body composition. Animals were 26
weeks of age at the time of DXA analysis. Three days following
DXA, mice were killed by cervical dislocation and decapitation,
and the left inguinal, left periovarian and left retroperitoneal white
adipose tissue (WAT) depots, as well as the whole mesenteric WAT
and the whole interscapular brown adipose tissue (BAT) depot
were removed and weighed. Data are expressed as absolute weight
or as grams per gram of body weight.
Measurement of spontaneous and fasting-induced food
intake
At 25 weeks of age, mice were transferred to litter-free
individual cages in order to accurately determine actual food
intake independently of the amount of food spilled on the cage
floor. Spontaneous 24-hour food intake measurements represent
an average of 3 days of measuring the amount of food taken from
the hopper minus the amount of food spilled. Fasting-induced
feeding was measured after fasting the mice for 24 h. Actual food
intake was measured as for spontaneous food intake at 1, 2, 3, 8
and 24 hours after reintroduction of food, and is expressed as
cumulative food intake. Body weight was measured at each time
point before and after fasting.
Indirect calorimetry
Metabolic rate was measured by indirect calorimetry using an
eight-chamber open-circuit calorimeter (Oxymax Series; Colum-
bus Instruments, Columbus, OH, USA). Pre-weighed mice at 26
weeks of age were housed individually in specially built Plexiglass
cages (20.1610.1612.7 cm). Temperature was maintained at
22uC with airflow of 0.6 1.min
21. Mice were singly housed for
food intake measurements before transferring into Plexiglass cages
and were acclimatized to the cages for 24 h before recordings
commenced. Mice were subsequently monitored in the system for
24 h. Oxygen consumption (VO2) and carbon dioxide production
(VCO2) were measured every 27 min. The respiratory exchange
ratio (RER) was calculated as the quotient of VCO2/VO2, with
100% carbohydrate oxidation resulting in a value of 1, and 100%
fat oxidation resulting in a value of 0.7 [23,24]. Energy
expenditure (kcal heat produced) was calculated as calorific value
(CV) x VO2, where CV is 3.815+1.2326RER [25], and the result
was normalized to lean mass as determined by DXA (described
above). Data for the 24-h monitoring period was averaged for 1-h
intervals for RER and energy expenditure.
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During indirect calorimetry, ambulatory activity was also
evaluated within the metabolic chambers using an OPTO-M3
sensor system (Columbus Instruments), whereby ambulatory
counts were a record of consecutive adjacent photo-beam breaks.
Cumulative ambulatory counts of X and Y directions were
recorded every minute and summed for 1-h intervals. The analysis
was made on mice of 26 weeks.
Glucose Tolerance Test
At 23 weeks of age, mice were fasted overnight and glucose
(Astra Zeneca, North Ryde, NSW, Australia) was injected
intraperitoneally at a dose of 1 g/kg. Blood glucose was measured
with the AccuCheck
TM blood glucose meter (Roche Diagnostics,
Mannheim, Germany) using blood samples taken from the tip of
the tail at the indicated time points.
Insulin Tolerance Test
At 24 weeks of age, mice were fasted for at least 5 hours (9:00 to
2.00–4:00 hours) and insulin (Novo Nordisk Pharmaceuticals,
Baulkham Hills, Australia) was injected intraperitoneally at a dose
of 1 U/kg. Blood glucose concentrations were determined as
described above using tail blood samples taken at the indicated
time points.
Statistical Analyses
Data were analyzed with t-tests or 2-way ANOVA followed by
Bonferroni post hoc tests if the genotype or interaction effect was
significant. Statistical analyses were performed with Prism
(GraphPad Software, Inc, LaJolla, USA). Differences were
regarded as statistically significant if p,0.05.
Acknowledgments
We thank the staff of the Garvan Institute Biological Testing Facility for
facilitation of these experiments.
Author Contributions
Conceived and designed the experiments: LM AS. Performed the
experiments: LM ADN HJ TK YCS SL. Analyzed the data: LM.
Contributed reagents/materials/analysis tools: SNB. Wrote the paper: LM
AS. Discussion: VWWT SL HH DAB. Edited the manuscript: HH DAB
SNB.
References
1. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, et al. (1997)
MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the
TGF-beta superfamily. Proc Natl Acad Sci U S A 94: 11514–11519.
2. Breit SN, Johnen H, Cook AD, Tsai VW, Mohammad MG, et al. (2011) The
TGF-beta superfamily cytokine, MIC-1/GDF15: a pleotrophic cytokine with
roles in inflammation, cancer and metabolism. Growth factors 29: 187–195.
3. Brown DA, Breit SN, Buring J, Fairlie WD, Bauskin AR, et al. (2002)
Concentration in plasma of macrophage inhibitory cytokine-1 and risk of
cardiovascular events in women: a nested case-control study. Lancet 359:
2159–2163.
4. Brown DA, Hance KW, Rodgers CJ, Sansbury LB, Albert PS, et al. (2011)
Serum macrophage inhibitory cytokine-1 (MIC-1/GDF15): a potential
screening tool for the prevention of colon cancer? Cancer epidemiology,
biomarkers & prevention: a publication of the American Association for Cancer
Research, cosponsored by the American Society of Preventive Oncology.
5. Wiklund FE, Bennet AM, Magnusson PK, Eriksson UK, Lindmark F, et al.
(2010) Macrophage inhibitory cytokine-1 (MIC-1/GDF15): a new marker of all-
cause mortality. Aging cell 9: 1057–1064.
6. Johnen H, Lin S, Kuffner T, Brown DA, Tsai VW, et al. (2007) Tumor-induced
anorexia and weight loss are mediated by the TGF-beta superfamily cytokine
MIC-1. Nat Med 13: 1333–1340.
7. Dostalova I, Roubicek T, Bartlova M, Mraz M, Lacinova Z, et al. (2009)
Increased serum concentrations of macrophage inhibitory cytokine-1 in patients
with obesity and type 2 diabetes mellitus: the influence of very low calorie diet.
European journal of endocrinology/European Federation of Endocrine
Societies 161: 397–404.
8. Ding Q, Mracek T, Gonzalez-Muniesa P, Kos K, Wilding J, et al. (2009)
Identification of macrophage inhibitory cytokine-1 in adipose tissue and its
secretion as an adipokine by human adipocytes. Endocrinology 150: 1688–1696.
9. Galic S, Oakhill JS, Steinberg GR (2010) Adipose tissue as an endocrine organ.
Molecular and cellular endocrinology 316: 129–139.
10. Karczewska-Kupczewska M, Kowalska I, Nikolajuk A, Adamska A, Otziomek E,
et al. (2012) Hyperinsulinemia acutely increases serum macrophage inhibitory
cytokine-1 concentration in anorexia nervosa and obesity. Clinical endocrinol-
ogy 76: 46–50.
11. Yadav H, Quijano C, Kamaraju AK, Gavrilova O, Malek R, et al. (2011)
Protection from obesity and diabetes by blockade of TGF-beta/Smad3
signaling. Cell metabolism 14: 67–79.
12. Zhang L, Macia L, Turner N, Enriquez RF, Riepler SJ, et al. (2010) Peripheral
neuropeptide Y Y1 receptors regulate lipid oxidation and fat accretion.
International journal of obesity 34: 357–373.
13. Tseng YH, Kokkotou E, Schulz TJ, Huang TL, Winnay JN, et al. (2008) New
role of bone morphogenetic protein 7 in brown adipogenesis and energy
expenditure. Nature 454: 1000–1004.
14. Van Heek M, Compton DS, France CF, Tedesco RP, Fawzi AB, et al. (1997)
Diet-induced obese mice develop peripheral, but not central, resistance to leptin.
The Journal of clinical investigation 99: 385–390.
15. Sainsbury A, Zhang L (2010) Role of the arcuate nucleus of the hypothalamus in
regulation of body weight during energy deficit. Molecular and cellular
endocrinology 316: 109–119.
16. Yaswen L, Diehl N, Brennan MB, Hochgeschwender U (1999) Obesity in the
mouse model of pro-opiomelanocortin deficiency responds to peripheral
melanocortin. Nature medicine 5: 1066–1070.
17. Patel HR, Qi Y, Hawkins EJ, Hileman SM, Elmquist JK, et al. (2006)
Neuropeptide Y deficiency attenuates responses to fasting and high-fat diet in
obesity-prone mice. Diabetes 55: 3091–3098.
18. Marino JS, Xu Y, Hill JW (2011) Central insulin and leptin-mediated autonomic
control of glucose homeostasis. Trends in endocrinology and metabolism: TEM
22: 275–285.
19. Banno R, Arima H, Hayashi M, Goto M, Watanabe M, et al. (2007) Central
administration of melanocortin agonist increased insulin sensitivity in diet-
induced obese rats. FEBS letters 581: 1131–1136.
20. Zarjevski N, Cusin I, Vettor R, Rohner-Jeanrenaud F, Jeanrenaud B (1994)
Intracerebroventricular administration of neuropeptide Y to normal rats has
divergent effects on glucose utilization by adipose tissue and skeletal muscle.
Diabetes 43: 764–769.
21. Bergen HT, Mizuno T, Taylor J, Mobbs CV (1999) Resistance to diet-induced
obesity is associated with increased proopiomelanocortin mRNA and decreased
neuropeptide Y mRNA in the hypothalamus. Brain research 851: 198–203.
22. Lin S, Storlien LH, Huang XF (2000) Leptin receptor, NPY, POMC mRNA
expression in the diet-induced obese mouse brain. Brain research 875: 89–95.
23. Ferrannini E (1988) The theoretical bases of indirect calorimetry: a review.
Metabolism: clinical and experimental 37: 287–301.
24. Frayn KN (1983) Calculation of substrate oxidation rates in vivo from gaseous
exchange. Journal of applied physiology: respiratory, environmental and
exercise physiology 55: 628–634.
25. McLean JA, Tobin G (1987) Animal and Human Calorimetry Cambridge
University Press.
Anti-Obesity Effects of MIC-1 in Mice
PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e34868